SCHEMBL4196607

SCHEMBL4196607

Cc1cc2ncccc2cc1Cc1nnc2ccc(-c3cnn(C)c3)nn12

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 20/20 0.76
PDE3B Q13370 3/20 0.61
PDE3A Q14432 3/20 0.61
NQO2 P16083 2/20 0.61
PIP4K2C Q8TBX8 2/20 0.61
ABL1 P00519 1/20 0.61
MAPK8 P45983 1/20 0.61
MAPK10 P53779 1/20 0.61
DYRK1A Q13627 1/20 0.61
MAP3K19 Q56UN5 1/20 0.61
DYRK1B Q9Y463 1/20 0.61
PDE2A O00408 1/20 0.59
CHRM2 P08172 1/20 0.59
PDE4A P27815 1/20 0.59
PDE1A P54750 1/20 0.59
PDE4B Q07343 1/20 0.59
PDE4C Q08493 1/20 0.59
PDE4D Q08499 1/20 0.59
PDE1C Q14123 1/20 0.59
PDE11A Q9HCR9 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12049124 0.90 MET (0.75) METPDE3BPDE3ANQO2PIP4K2C
SCHEMBL2492185 0.86 MET (1.00) METPDE3BPDE3ANQO2PIP4K2C
SCHEMBL14198919 0.84 MET (0.54) MET
SCHEMBL12049136 0.83 MET (0.74) METPDE3BPDE3ANQO2PIP4K2C
SCHEMBL4500316 0.82 MET (0.76) METPDE3BPDE3ANQO2PIP4K2C
SCHEMBL12049105 0.81 MET (0.73) METPDE3BPDE3APDE1APDE4C
SCHEMBL14345887 0.81 MET (0.67) MET
SCHEMBL2494598 0.80 MET (0.79) METPDE3BPDE3ANQO2PIP4K2C
SCHEMBL12049114 0.79 MET (0.61) MET
SCHEMBL12049135 0.79 MET (0.73) METPDE3BPDE3ANQO2PIP4K2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2032578-A2 TRIAZOLOPYRIDAZINE DERIVATIVES Pfizer Products Incorporated (US) 2009-03-11 EP claimed
WO-2007138472-A2 TRIAZOLOPYRIDAZINE DERIVATIVES PFIZER PRODUCTS INC. (US) 2007-12-06 WO claimed
US-8071581-B2 Triazolopyridazine protein kinase modulators SGX PHARMACEUTICALS, INC. (US) 2011-12-06 US disclosed
US-8071581-B2 Triazolopyridazine protein kinase modulators SGX PHARMACEUTICALS, INC. (US) 2011-12-06 US disclosed
US-20100120739-A1 TRIAZOLOPYRIDAZINE PROTEIN KINASE MODULATORS SGX PHARMACEUTICALS, INC. 2010-05-13 US disclosed
US-20100120739-A1 TRIAZOLOPYRIDAZINE PROTEIN KINASE MODULATORS SGX PHARMACEUTICALS, INC. 2010-05-13 US disclosed
EP-2032578-A2 TRIAZOLOPYRIDAZINE DERIVATIVES Pfizer Products Incorporated (US) 2009-03-11 EP disclosed
WO-2008051805-A2 TRIAZOLO-PYRIDAZINE PROTEIN KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2008-05-02 WO disclosed
WO-2007138472-A2 TRIAZOLOPYRIDAZINE DERIVATIVES PFIZER PRODUCTS INC. (US) 2007-12-06 WO disclosed
WO-2007138472-A2 TRIAZOLOPYRIDAZINE DERIVATIVES PFIZER PRODUCTS INC. (US) 2007-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120739-A1 TRIAZOLOPYRIDAZINE PROTEIN KINASE MODULATORS MAP4K5, MAPKAPK5, MAP4K2 MET 1025/4885PDE3B 600/4885PDE3A 568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.